UPDATE: Prothena Corp. (PRTA) Reports Q1 EPS Loss of $1.26

Prothena Corp. (NASDAQ: PRTA) reported Q1 EPS of ($1.26), $0.73 worse than the analyst estimate.

• Net cash used in operating and investing activities was $31.8 million in the first quarter; quarter-end cash and restricted cash position of $433.1 million supports advancement through key milestones of R&D pipeline
• Entered into global neuroscience research & development collaboration with Celgene to advance novel therapies for patients with neurodegenerative diseases
• Initiated a first-in-human study of PRX004 in patients with ATTR amyloidosis

For earnings history and earnings-related data on Prothena Corp. (PRTA) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• B.C. households cutting back on groceries and essentials as cost-of-living crisis worsens: new survey
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth